Voltage-gated sodium (Na V ) channels are essential for the transmission of pain signals in humans making them prime targets for the development of new analgesics. Spider venoms are a rich source of peptide modulators useful to study ion channel structure and function. Here we describe β/δ-TRTX-Pre1a, a 35-residue tarantula peptide that selectively interacts with neuronal Na V channels inhibiting peak current of hNa V 1.1, rNa V 1.2, hNa V 1.6, and hNa V 1.7 while concurrently inhibiting fast inactivation of hNa V 1.1 and rNa V 1.3. The DII and DIV S3-S4 loops of Na V channel voltage sensors are important for the interaction of Pre1a with Na V channels but cannot account for its unique subtype selectivity. Through analysis of the binding regions we ascertained that the variability of the S1-S2 loops between Na V channels contributes substantially to the selectivity profile observed for Pre1a, particularly with regards to fast inactivation. A serine residue on the DIV S2 helix was found to be sufficient to explain Pre1a's potent and selective inhibitory effect on the fast inactivation process of Na V 1.1 and 1.3. This work highlights that interactions with both S1-S2 and S3-S4 of Na V channels may be necessary for functional modulation, and that targeting the diverse S1-S2 region within voltage-sensing domains provides an avenue to develop subtype selective tools.
isoforms Na V 1.3, Na V 1.8 and Na V 1.9 have also been implicated in various forms of chronic and acute pain [9] [10] [11] [12] , whereas recent evidence suggests that Na V 1.1 also plays a role in mechanical pain transmission 13 . However, the similarity between Na V channel α-subunits poses a challenge to discover and develop molecules that can selectively modify the function of each subtype.
Natural toxins have been instrumental in defining Na V channel subtypes and many of the known functionally relevant binding sites on the channel 1 . In recent decades, venom peptides have proven to be an invaluable source of novel, selective, and potent modulators of ion channels, leading to an increasing interest in these molecules as pharmacological tools and potential therapeutic leads 14 . In this respect, spiders possibly represent one of the richest sources of novel voltage-gated channel modulators 15 that not only target channel α-subunits, but also complexes containing the accessory β-subunits 16 . A majority of currently characterised Na V channel modulating spider venom peptides share a common structural motif of the inhibitory cysteine knot (ICK) and interact with one of four VSDs at partially defined receptor sites 17, 18 .
These VSD modulating peptides have been described to modify channel gating in three distinct ways depending on the domain they target and the effect on that domain 17 . Domain IV of the Na V channel α-subunit uniquely controls inactivation of the channel 19 , thus spider peptides that interact with and hinder the normal function of VSDIV slow or inhibit fast inactivation of the channel and may result in persistent current 20 . Conversely, spider venom peptides that interact with DI, DII, and DIII VSD modulate channel activation 21 . Most of those discovered to date cause a shift in the voltage-dependence of activation in the depolarising direction and inhibit activation 22, 23 , whereas some such as β-HXTX-Mg1a (Magi 5) cause a hyperpolarising shift, thereby facilitating activation 24 . The VSDs of different voltage-gated ion channels exhibit higher sequence variability than the highly conserved pore region, thus offering the opportunity for subtype-selective interactions between Na V subtypes as well as the greater voltage-gated ion channel superfamily. Indeed, certain families of spider venom peptides demonstrate remarkable subtype selectivity profiles 13, 25 .
A deeper understanding of the molecular basis of the interactions between spider venom peptides with Na V channels is helping efforts to design a new generation of pharmacological tools and potential therapeutic lead molecules [26] [27] [28] . To this end, we identified β/δ-TRTX-Pre1a (Pre1a) from the venom of the tarantula Psalmopoeus reduncus in a screen for Na V 1.7 inhibitors. Pre1a exhibited a unique and complex pharmacological profile across neuronal Na V channel subtypes where it preferentially inhibits fast inactivation of Na V 1.3, inhibits activation of Na V 1.2, Na V 1.6, and Na V 1.7, and inhibits both activation and fast inactivation of Na V 1.1, with no effect on Na V 1.4 or Na V 1.5 at sub-micromolar concentrations. This functional profile is dictated by classical interactions with the DII and DIV S3-S4 loops of the Na V channel VSDs. However, our evidence points to the S1-S2 loops as critical for imparting the isoform selectivity demonstrated by Pre1a. Pre1a thus represents a valuable tool to study the subtle differences in DII and DIV interaction sites between members of the Na V channel family.
Results
Isolation and sequence of TRTX-Pre1a. In a small screen of 14 spider venoms, Psalmopoeus reduncus venom at 1:1000 dilution (~200 μg/ml) consistently and potently inhibited human (h) Na V 1.7 expressed in Xenopus laevis oocytes. Activity-guided fractionation resulted in the identification of a major component exhibiting inhibitory activity at hNa V 1.7 expressed in oocytes (Fig. 1a ). The purified peptide eluted with an unusual, leading minor peak that upon mass analysis revealed the same M + H + of 4227.5 as the principal peak ( Fig. 1b) and was found to inhibit both the of peak current of hNa V 1.7 and the inactivation of rat (r) Na V 1.3 (Fig. 1c ). The mass of the reduced/alkylated peptide was 588 Da higher than the native peptide (6 × 98, the MW of maleimide), indicating the presence of three disulfide bonds (data not shown). Edman analysis of the reduced/alkylated peptide resulted in complete sequence determination of a novel 35 amino acid peptide with high sequence similarity to several Na V modulating spider venom peptides ( Fig. 1d ), determined by a search of non-redundant protein database (NCBI). Sequences were aligned and percent similarity calculated manually. Taking into account disulfide bonds, the observed monoisotopic M + H + (4227.5) matched that of the theoretical M + H + with a free acid C-terminus (4226.9, Expasy-PeptideMass) that was confirmed using MSMS on tryptic digest fragments (data not shown). The peptide was named TRTX-Pre1a (Pre1a) according to the current rational nomenclature 29 .
In order to carry out functional characterisations, we produced Pre1a using Boc solid-phase peptide synthesis. The folded synthetic peptide co-eluted with the peptide isolated from the native source (Supp. Fig. 1 ). Analytical RP-HPLC analysis of synthetic Pre1a revealed that the unusual non-symmetrical nature of the eluting peptide is an inherent property of the peptide and suggested that Pre1a is structurally heterogeneous (Fig. 2 ). This structural heterogeneity was confirmed by collecting the body and trailing portions of the major peak as individual fractions then re-injecting under the same conditions, whereupon the same non-symmetrical chromatographic profile was observed ( Fig. 2 insets) . This suggests a conformational (chemical) exchange process that is slow on the HPLC time scale.
Structural studies of recombinant Pre1a. Preliminary homonuclear NMR analysis of synthetic Pre1a
confirmed the presence of conformational heterogeneity, prompting us to isotope label the peptide (using recombinant expression in E. coli, Supp. Fig. 2 ) to enable less ambiguous heteronculear NMR analysis. Backbone resonance assignments ( 1 H N , 15 N, 13 C α , 13 C β , 13 C′) for rPre1a were completed by analysis of the 3D HNCACB, CBCA(CO)NH, and HNCO spectra, and the side chain 1 H and 13 C chemical shifts from the 3D H(CC) (CO) NH-TOCSY and (H)CC(CO)NH-TOCSY spectra, respectively. Together we achieved 90% completion of all proton assignments. However, due to the structural heterogeneity, insufficient unique constraints were derived from the NOESY spectra to enable the structure calculations using CYANA 30 to produce a adequately converged high-resolution structure. However, the chemical shifts determined for the backbone resonances allowed us to predict the secondary structure of Pre1a using the program TALOS+ 31 , which suggests that residues around C3-L4 and Y21-K22 are likely to form β-strands (Supp. Fig. 3a ). (c) Activity of pure, native Pre1a on rNa V 1.3 and hNa V 1.7 exressed in Xenopus oocytes demonstrating inhibition of inactivation and peak current, respectively. (d) Sequence alignment of TRTX-Pre1a with Na V modulating Theraphotoxins 13, 20, 22, 41, 47-50, 55, 65-68 . Percent similarity was calculated comparing the number of identical (dark gray) and similar (light gray) amino acids.
Figure 2.
Pre1a shows conformational flexibility under RP-HPLC conditions. Analytical RP-HPLC of pure synthetic Pre1a shows the presence of multiple conformers in and acetonitrile/water mixture at room temperature. Insets 1 and 2, demonstrate identical elution profiles for reinjection of two fractions (highlighted and numbered) taken from the major peak, discounting the presence of impurities. Furthermore, the NMR data allowed us to confidently determine the disulfide connectivity of the peptide via unambiguous NOEs between sidechain C β filtered H β protons. NOEs could be observed between the side chain protons of C3 and C18, C10 and C23 and C17 and C30 in the 13 C-NOESY (Supp. Fig. 3b ), consistent with the formation of the common ICK-motif (C1-C4, C2-C5, C3-C6), which appears to be the dominant structural scaffold among Na V channel modulating spider venom peptides characterised to date.
The 3D NMR data also allowed us to characterise the conformational heterogeneity of Pre1a, first observed on RP-HPLC. The presence of several peptide conformations resulted in multiple backbone 1 H N / 15 N chemical shifts for residues D2-R9 in the 15 N-HSQC spectrum, exemplified by G5 ( Fig. 3a ). These residues form Loop 1 and, with the exception of S8 and R9 (which have duplicate peaks), all have visible triplicate peaks with decreasing intensities (for examples of NMR experiments on related but structurally rigid peptides see Fig. 2 in Lau et al. 32 and Fig. S3 in Klint et al. 33 ). Additionally, a homology model of Pre1a was constructed using the structure of HwTx-IV as a template (PDB 2M4X) 34 using SWISS-MODEL 35 . The Pre1a model shows a highly dense packing of five aromatic residues with W6 and F7 at the tip of Loop 1 falling between W29 and Y32/Y21 on one face of the peptide (Fig. 3b ). We hypothesise that this overcrowding of bulky aromatic side chains results in the structural flexibility of Pre1a as seen in both aqueous (NMR) and hydrophobic (RP-HPLC) conditions. Pre1a affects neuronal Na V channels in a subtype-dependent manner. Pre1a produced by either chemical synthesis or recombinant expression was equipotent at inhibiting the peak current of hNa V 1.7 (Supp. Fig. 4a ). β-subunits can have profound effects on venom peptide interactions with Na V channels 36 , however Pre1a's inhibitory effect on hNa V 1.7 was not modified by the accessory β1 subunit (Supp. Fig. 4b ). To determine the subtype selectivity profile of recombinant Pre1a it was tested on five different Na V channel α-subunits expressed in X. laevis oocytes ( Fig. 4a ). Pre1a concentration-dependently inhibited the peak inward current of rNa V 1.2 and hNa V 1.7 with IC 50 values of 189.6 nM (pIC 50 6.72 ± 0.06) and 114.0 nM (pIC 50 6.94 ± 0.06), respectively ( Fig. 4b) , and weakly inhibited rNa V 1.3 with an IC 50 of 8.0 μM (pIC 50 5.10 ± 0.05). Similar to its effect on Na V 1.3, 1 μM Pre1a only weakly inhibited the peak current amplitude of rNa V 1.4 and hNa V 1.5 by 16.47 ± 0.05% and 8.60 ± 0.05%, respectively ( Fig. 4b ).
Pre1a demonstrated inhibitory effects on rNa V 1.3 fast inactivation ( Fig. 4a ), thus these effects on Na V 1.2, 1.3 and 1.7 were examined in detail. We analysed the rate of fast inactivation (defined as tau, τ inact , or the time to reach 36.8% of a single exponential fit of the current decay) and the degree of persistent sodium current measured at 50 ms of depolarisation (Na V 1.2 and 1.7) and 100 ms for rNa V 1.3 due to the longer time required to reach complete inactivation in the oocyte expression system without β1. Consistent with results observed during assay-guided fractionation, Pre1a potently inhibited the inactivation of rNa V 1.3 with an EC 50 of 45.5 nM (pEC 50 Figure 4 . Pre1a preferentially inhibits neuronal Na V channels. (a) Representative Na V currents recorded from Xenopus oocytes (α-subunit alone) before addition of 1 µM Pre1a (black) and after reaching steady state inhibition (red). Late current was assessed at 50 ms (100 ms for Na V 1.3) from the peak current, as highlighted by the grey box on rNa V 1.3. (b) Concentration-effect curves for peak current inhibition by Pre1a for rNa V 1.2 (IC 50 189.6 nM; n ≥ 5), rNa V 1.3 (IC 50 7.34 ± 0.27) ( Fig. 4a and c), a selectivity of more than 150-fold for inhibiting rNa V 1.3 inactivation over activation. In addition to inhibiting the extent of rNa V 1.3 inactivation (as indicated by the level of persistent current), Pre1a also decreased the rate of current inactivation, reflected as a concentration-dependent increase in τ inact (Fig. 4d ). At 1 μM, a concentration that almost completely inhibited rNa V 1.2 and hNa V 1.7 currents, Pre1a had no significant effect on the persistent current or τ inact of either of these channels. There was no apparent effect of 1 μM Pre1a on the inactivation of either rNa V 1.4 or hNa V 1.5 (Fig. 4a ).
Spider venom peptides similar to Pre1a have been shown to target Na V 1.1 and Na V 1.6 22, 28 , thus we assessed the activity of Pre1a on hNa V 1.1 and hNa V 1.6 stably expressed in HEK cells using the Qpatch16 automated patch-clamp platform (Fig. 4e ). To compare possible discrepancies in potency between the two different systems, HEK-hNa V 1.7 cells were tested in parallel. Pre1a inhibited hNa V 1.1, hNa V 1.6, and hNa V 1.7 with IC 50 s of 57.1 nM (pIC 50 7.24 ± 0.07), 221.6 nM (pIC 50 6.65 ± 0.06), and 15.0 nM (pIC 50 7.82 ± 0.04), respectively ( Fig. 4f ). An approximate 7-fold increase in potency was determined for the inhibition of hNa V 1.7 peak current as analysed on the QPatch as compared to the IC 50 obtained for this channel in oocytes. A difference in potency of some molecules or with some receptors is not uncommon when comparing two-electrode voltage clamp of oocytes to data obtained using whole-cell patch clamping of mammalian cells [37] [38] [39] .
In addition to the effect of Pre1a on Na V 1.1 peak current, it also equipotently inhibited Na V 1.1 fast inactivation with an EC 50 of 41.4 nM (pEC 50 7.38 ± 0.51) ( Fig. 4g ). Beyond 1 µM, inhibition of peak current prevented the analysis of inactivation as the current was fully inhibited. Concentrations up to 1 μM Pre1a on hNa V 1.6 or up to 300 nM on hNa V 1.7 had no effect on inactivation ( Fig. 4g ). Together, these results demonstrate that Pre1a has a strong preference for modulating neuronal Na V channel isoforms over the skeletal muscle (Na V 1.4) and the cardiac (Na V 1.5) isoforms. Using the IC 50 for inhibition of Na V 1.7 peak current as a reference point (to allow comparison across platforms) results in a relative rank order potency for Na V modulation of rNa V 
Thus the effect of Pre1a on Na V 1.3 inactivation has the highest relative potency for all Na V activity (peak current or inactivation) on the channels tested.
Pre1a modulates Na V channel function by inhibiting channel gating. The mechanism of action of Pre1a was studied by determining the voltage of half maximal effect (V 1/2 ) of channel gating for rNa V 1.2, rNa V 1.3 and hNa V 1.7 expressed in oocytes ( Fig. 5 ). Pre1a (1 µM) significantly shifted the V 1/2 of rNa V 1.2 and hNa V 1.7 activation by +14.9 mV and +13.8 mV, respectively ( Fig. 5a ), whilst having no effect on the V 1/2 of activation of rNa V 1.3 peak current ( Fig. 5b) . Pre1a had no effect on the V 1/2 of inactivation of rNa V 1.2 or hNa V 1.7 (Fig. 5a ) or rNa V 1.3, however, it did prevent the current of Na V 1.3 from fully inactivating (Fig. 5b) . In contrast, 1 μM Pre1a shifted the V 1/2 of activation of the rNa V 1.3 late current by +9.6 mV ( Fig. 5c ).
Depolarising shifts in the activation of rNa V 1.2 and hNa V 1.7 and of the rNa V 1.3 late current are consistent with inhibition of channel gating via interactions with the voltage-sensing domains of repeat II and IV, respectively. Therefore, Pre1a is clearly a gating modifier that interacts with Na V channels in a subtype-dependent manner. As Pre1a inhibits both Na V channel activation and fast inactivation, we propose using the prefix β/δ according to the proposed nomenclature for spider venom peptides 29 .
Pre1a interacts with the S3-S4 linkers of hNa V 1.7 DII and DIV. The extracellular S3-S4 linker region has been demonstrated to play a key role as a binding determinant for spider venom peptides to voltage-sensing domains 18, 40 . Given that Pre1a potently affects the activation of hNa V 1.7, we wanted to determine if this inhibition was mediated via interactions with a specific voltage-sensor domain. To this end, we used the approach of Bosmans et al., whereby the S3-S4 linker region of the K V 2.1 channel was substituted with corresponding linker region of hNa V 1.7 DI to DIV 18, 41 . The effect of Pre1a on the resultant K + current was then tested for native K V 2.1 and each of the domain chimaeras. Pre1a (1 μM) had no effect on wild-type K V 2.1 or the DI and DIII chimaeras, however it inhibited outward current carried by the Na V 1.7 DII and DIV/K V 2.1 chimaeras by 44.0 ± 4.6% and 27.1 ± 3.8% (n = 6), respectively ( Fig. 6a and b) . Several of the residues crucial for the interaction of HwTxIV with the DII S3-S4 region of Na V 1.7 as determine by Xiao et al. 23 are also present in DIV, but not in the S3-S4 linker of Na V 1.7 DI, DIII or Kv2.1 (Fig. 6c ), which supports our observation of weaker effect of Pre1a on the DIV chimaera than the DII chimaera. Interaction with DII is completely consistent with Pre1a's inhibition of Na V 1.7 activation. Interestingly, the interaction with the Na V 1.7 DIV/K V 2.1 chimaera suggests that Pre1a should have an effect on the inactivation of hNa V 1.7, as was noted for hNa V 1.1 and rNa V 1.3. However, we observed no effects of Pre1a on the inactivation of Na V 1.7 at up to 1 μM in oocytes or 300 nM in HEK cells. These results suggest that an interaction with the S3-S4 linker alone is not sufficient to result in a potent functional effect on DIV, consistent with the effects of the spider peptide δ-Hm1a on Na V 1.1 13 .
Pre1a requires interactions with S3-S4 and S1-S2 regions to produce a functional effect at DIV. The results above show that Pre1a has potent and subtype-dependent effect on Na V channel gating. It potently inhibits the activation (DII effect) of hNa V 1.1, rNa V 1.7 and rNa V 1.2, but not rNa V 1.3, whereas it selectively inhibits the inactivation (DIV effect) of Na V 1.1 and 1.3, but not 1.2 or 1.7. The striking differences in effects on Na V 1.1, 1.2 and 1.3 are of particular significance for understanding the molecular basis of Pre1a's subtype selectivity as these three channels have essentially identical S3-S4 linker regions in both DII and DIV (Fig. 7a ) (note that Na V 1.1 DII S3-S4 has an M to V substitution at the top of the S3 helix). Thus, this region cannot account for the substantial differences in Na V channel subtype selectivity observed for Pre1a. The S1-S2 linker region has previously been shown to contribute to the interaction of HwTxIV with Na V 1.7 via E753 a the top of S1 23 . This residue is highly conserved in all Na V channels, thus it cannot account for the subtype selectivity that we observed. Figure 7a shows that there is sufficient sequence variation between Na V 1.1, 1.2, 1.7 and 1.3 in the first half of S2 of DIV (indicated as 1, 2 and 3) to possibly explain our data. Previous mutagenesis studies on DII 23 and DIV 13 have shown that the divergent residues in region 1 have little effect on the activity of HwTxIV and δ-Hm1a, respectively. As region 3 of helix S2 is identical in both Na V 1.1 and Na V 1.3, but not 1.2 and 1.7, we assessed the potential role of these two residues (Ser/Arg) in the ability of Pre1a to inhibit inactivation. Using a chimaera-based approach we found that replacing the S3-S4 linker of rNa V 1.4 (Pre1a insensitive) with corresponding linker from hNa V 1.1 (Pre1a sensitive) was not sufficient to allow inhibition of inactivation by Pre1a (1 μM) (Fig. 7b,c and d ). Using the rNa V 1.4 (1.1:S3-S4) background, introduction of Ser1379 (S1574 in hNa V 1.1), but not Arg1380 from Na V 1.1 S1-S2 was sufficient for Pre1a to have a functional effect on both the extent (Fig. 7c ) and rate (Fig. 7d ) of fast inactivation.
Effects of Pre1a on SH-SY5Y human neuroblastoma cells and rat dorsal root ganglion neurons.
As reported previously, Na V 1.2, Na V 1.3 and Na V 1.7 (but not Na V 1.1 or Na V 1.6) are robustly expressed in the human neuroblastoma cell line, SH-SY5Y 42 . Therefore, synthetic Pre1a was tested on SH-SY5Y cells using manual patch clamp to assess the effects on native human Na V channel currents. As shown in Fig. 8 , 300 nM Pre1a inhibited the rapid peak Na + current in a manner consistent with previously observed effects on rNa V 1.2 and hNa V 1.7, while concurrently slowing fast inactivation as was observed with rNa V 1.3. This suggests that endogenously expressed hNa V 1.3 exhibits similar sensitivity to Pre1a as compared to the rat isoform expressed in oocytes.
Additionally, small DRG neurons were excised from both sham and peripheral nerve ligated (PNL) adult rats, 7 days post operation. In both sets of DRG neurons, 300 nM synthetic Pre1a inhibited the peak Na + current and slowed fast inactivation in a manner comparable to SH-SY5Y cells (Fig. 8 ). Na V 1.3 expression is barely detectable in Sprague-Dawley rats at 30 days post-natal 43 and it has been shown that this channel is upregulated and highly expressed in sensory neurons after 7-9 days post axotomy of peripheral, but not central axons 44, 45 . Therefore, minimal effects on fast inactivation of neurons from sham rats were expected, but a substantial effect on the fast inactivation of DRG neurons from post-PNL rats was expected but not observed (Fig. 8b) . This result was surprising, as developmental and post-injury regulation of Na V 1.3 would suggest this channel should not play a significant role in conductance for adult DRG neurons isolated from sham animals. We showed that Pre1a (at Scientific RepoRts | 7: 974 | DOI:10.1038/s41598-017-01129-0 30 nM) also inhibits fast inactivation of Na V 1.1 but not Na V 1.6, thus the persistent current observed with Sham rat DRG neurons in the presence of Pre1a is likely due to effects on Na V 1.1, which is present in adult neurons and has been reported to not undergo regulatory changes post-axotomy 13, 46 .
Discussion
We have identified and characterised β/δ-TRTX-Pre1a, a tarantula venom peptide that potently modulates neuronal Na V channels and possesses a unique structural and pharmacological profile. Pre1a exhibits over 70% sequence similarity with several other spider venom peptides (e.g. PaurTx3, CcoTx1, GpTx1 and Ccy1b 22, 41, 47 ); however, the toxin is unique among these peptides in its ability to potently and selectively inhibit fast inactivation of Na V 1.1 and Na V 1.3. Furthermore, Pre1a shows a marked structural heterogeneity/flexibility in both aqueous and organic solvents, which may be related to its unique activity profile when compared to its closest sequence relatives. Thus, Pre1a represents a valuable research tool to help determine the molecular basis for spider venom peptide interactions with multiple modulatory sites in sodium channels, particularly in respect to effects on fast inactivation. Na V channel fast inactivation is controlled by the movement of the DIV voltage-sensing domain 17 . Although several spider venom peptides (such as JzTxI and JzTxII) have previously been shown to preferentially inhibit Na V channel fast inactivation, they are either relatively non-selective 48 or preferentially target Na V 1.5 49, 50 . Two other spider peptides (ProTx-II and JzTxIV) have been found to inhibit both peak current and fast inactivation of Na V channels 20, 25 , much like Pre1a. However, all these peptides share less than 50% similarity with Pre1a (See Fig. 1d ) and have very different subtype selectivity profiles suggesting that Pre1a can help define the basis for subtype selective interactions with DIV. Indeed, through a series of functional experiments using channel chimaeras and point mutants, we demonstrated that a serine residue in the S2 helix of DIV that is unique to hNa V 1.1 (S1574) and rNa V 1.3 (S1510) is responsible for the selective modulation of fast inactivation by Pre1a. Our results are consistent with several reports suggesting that this serine residue is a major determinant for the impressively subtype selective effects of both small molecule drugs and another spider venom peptide not related to Pre1a. ICA-121431 inhibits hNa V 1.3 and hNa V 1.1 peak current with ~1000-fold selectivity and functions by trapping the DIV VSD in the activated state (stabilising fast inactivation, rather than inhibiting it) 51 , whereas δ-TRTX-Hm1a (Hm1a) was recently characterised as a selective inhibitor of inactivation of Na V 1.1 13 , having been previously discovered as a low-affinity K V 4.2 inhibitor 52 . Furthermore, a co-crystal structure of a Na V 1.7 VSD IV chimaera with the small molecule Na V channel inhibitor GX-936 has been solved revealing the detailed molecular interactions responsible for its selectivity 53 . GX-936 has the same mechanism of action as ICA-121431 thus arrests the VSD in the inactivated state as opposed to the resting state targeted by Pre1a and Hm1a. Remarkably, and despite the different state stabilised by these peptides and small molecules, they all rely on the same region in S2 (S1574 in hNa V 1.1 and neighbouring residues) for their functional selectivity. Together, these results illustrate that the S2 helix is Figure 7 . The S3-S4 linker alone accounts for the subtype selectivity of Pre1a. (a) Alignment of DII and DIV extracellular linkers S1-S2 and S3-S4 for Na V channel isoforms used in this study. Grey shading indicates identity to rNa V 1.3 for both domains, residue colouring indicates; blue = basic/positive, red = acidic/negative, green = polar, black = hydrophobic. Helices are defined based on the structures of rabbit Ca V 1.1 (PDB: 5GJV) for DII, and the Na V Ab/hNa V 1.7 chimaera (PDB: 5EK0) for DIV. *Indicates residues mutated in DII by Xiao et al. 23 , red highlight indicates importance for HwTxIV interaction. an important locus for subtype selective modulation of Na V channel fast inactivation and that the key residues involved appear to be accessible to ligands in both the resting and inactivated states.
Although Hm1a and Pre1a share the ability to inhibit Na V 1.1 fast inactivation, they differ greatly in primary sequence (only 17% similarity when excluding the structurally critical Cys residues). Interestingly, the small amount of similarity that does exist between them is a hydrophobic patch clustered in loop 1 of the peptide (Fig. 1d ). Co-incidentally this is the region of Pre1a that is structurally mobile, a characteristic that has not been reported for venom peptides most closely related to Pre1a and that seem to predominantly inhibit channel activation 22, 41, 47 . From extensive structure-activity studies carried out by several pharmaceutical companies on spider venom peptides closely related to Pre1a (i.e. GpTx1, CcoTx1 and HwTxIV [26] [27] [28] 34 ), the aromatic residues at the tip of Loop 1 are key residues for the interaction of these peptides with Na V channels, in particular for their inhibitory effects on channel activation. Whether the flexibility of loop 1 in Pre1a has any role in its ability to potently interact with both DII and/or DIV VSDs (i.e., resulting in two conformations of the same pharmacophore residues) remains to be elucidated.
The interactions of spider venom peptides that inhibit Na V channel activation have been the focus of extensive chimaera and scanning mutagenesis studies to characterise the binding site on the channel. Bosmans et al. demonstrated that the S3-S4 linker region of any of DI to DIII can be a primary binding determinant for a number of venom peptides by transplanting this region in to a toxin insensitive background and transferring functional peptide binding 18 . Subsequently, a motif, which spans the DII S1-S2 and S3-S4 regions, that is critical for the inhibitory activity of HwTx-IV on hNa V 1.7 was identified and consists of the residues E753 in S1, and E811, L814, D816, E818 in S3-S4 23 (See red asterisks in Fig. 7a ). This has since been functionally demonstrated for two other spider peptides with substantial similarity to Pre1a 54, 55 as well as suggested structurally (in solution using NMR) for the interaction of VSTX1 and the VSD of K V Ap 32 . Our data showing a greater effect of Pre1a on the DII Kv2.1/hNav1.7 S3-S4 chimaera than that containing the DIV S3-S4 linker is in accord with the these previous studies. However, interaction with the residues identified in S1 and S3-S4 does not explain the substantial differences in Pre1a's ability to inhibit Na V channel activation and despite the studies carried out to date, little insight into the basis of Na V channel subtype selectivity has been gained in regards to DII. Pre1a most potently inhibited the activation of Na V 1.7 and Na V 1.2 with ~70-fold selectivity over Na V 1.3. The latter two channels have identical sequences in the S3-S4 linker, thus binding to this region cannot account for the observed selectivity. Interestingly hNa V 1.1 and rNa V 1.2 only differ by only two residues in the S2 helix, a conservative Thr (1.3) to Ser (1.2) substitution (at the position corresponding to the Ser1574 in Nav1.1 DIV) and a less conservative Gln (1.3) to Glu (1.2) substitution at the top of S2. This strongly suggests that residues in one or both of these positions make major contributions to the interaction of Pre1a with Na V VSD (driven primarily by interactions with S3-S4) that together result in functional inhibition of the channel. Thus, similar to what we showed for the molecular basis of sub-type selective inhibition of inactivation, subtype selective interactions at DII are also likely determined by the variability in the S2 helix.
In conclusion, we have identified a novel spider venom peptide and demonstrated how its so far unique activity on the Na V channel family can be used to gain insight into the molecular basis of subtype selectivity. It should be noted that few venom peptide modulators of Na V channels have been studied in the same detail as reported here, thus the structural heterogeneity and binding site promiscuity of Pre1a may indeed be a more common property than we realise. Pre1a has great value as a research tool for exploration of the selectivity profile of activation and inactivation on different Na V channel isoforms, as well as exploring the consequences and effects of conformational flexibility to activity in this family of channel modulators.
Methods

Venom peptide purification. Psalmopoeus reduncus venom was purchased from SpiderPharm (Yarnell).
Venom was fractionated using a C18 218TP54 column Bacterial recombinant production of Pre1a. Pre1a was produced recombinantly using an E. coli periplasmic expression system as described previously 57 . Briefly, a synthetic gene encoding Pre1a was codon optimised for bacterial expression and subcloned into a pLicC-His 6 -MBP periplasmic expression vector, where the peptide is expressed as a C-terminal fusion to His 6 -tagged maltose binding protein (MBP) separated by a tobacco etch virus (TEV) protease cleavage site, leaving an additional N-terminal Ser after cleavage. Fusion proteins were expressed in E. coli strain BL21(λDE3) and isolated from cell lysates using Ni-NTA Superflow resin (Qiagen). The His 6 -MBP tag was removed from the fusion protein using TEV protease, and recombinant Pre1a purified using RP-HPLC.
For production of uniformly 13 C/ 15 N-labelled Pre1a, cultures were grown in minimal medium supplemented with 13 C 6 -glucose and 15 NH 4 Cl as the sole carbon and nitrogen sources, respectively. In order to facilitate comparisons between synthetic and recombinant Pre1a, residue numbers for the native toxin are used throughout the text even though the recombinant toxin contains an additional N-terminal serine residue that is a vestige of the TEV cleavage site.
Two-electrode voltage clamp analysis on Na V channel-expressing oocytes. The preparation and
injection of Xenopus laevis oocytes and Na V channel recordings using two-electrode voltage-clamp (TEVC) were carried out as described previously 58 . Capped cRNA encoding rat Na V 1.2, Na V 1.3 and Na V 1.4, and human Na V 1.5 and Na V 1.7 were injected at 20-40 ng of cRNA/oocyte and kept at 17-18 °C in ND96 solution containing (in mM) 96 NaCl, 2 KCl, 1 CaCl 2 , 2 MgCl 2 , 5 HEPES, 5 pyruvic acid, 50 µg/ml gentamicin (pH 7.4), and horse serum (2.5%). Membrane currents were recorded 2-5 days after injection. Oocytes were clamped at −90 mV and currents were elicited by a 50 ms depolarising step to −10 or 0 mV every 10 s for concentration response curves. Both peak and late current (50 ms post peak) were analysed. The concentration response curves were fitted to the Hill equation (GraphPad Prism 6). Current-voltage (I-V) relationships and voltage-dependence of fast inactivation were determined using a family of 100 ms conditioning pulses from −100 mV to +50 mV (+60 mV for rNa V 1.3) in 5 mV steps, followed by a test depolarisation step to 0 mV with a 20 s sweep interval from a holding potential of −90 mV. To determine the voltage-dependence of activation non-normalised peak current was used from the I-V family to calculate channel conductance using the equation: G(V) = I/(V − V rev ), in which I, V, and V rev represent inward Na V current, test potential, and reversal potential, respectively. The half-activation potential (V 1/2 ) was determined using a Boltzmann fit (GraphPad Prism 6). All data points are shown as the pIC 50 ± S.E.M., as well as the IC 50 . Replicates (n) represent separate experimental oocytes. Pre1a was resuspended in ND96 solution containing 0.1% bovine serum albumin for all activity analysis. Construction and recording of the K V 2.1chimaeras containing hNa V 1.7 DI-DIV S3-S4 linker regions was completed as described previously 18, 41 . Design and construction of the hNa V 1.1/rNa V 1.4 DIV chimaeras is detailed in Osteen et al. 13 . Not all isoforms of Na V s from the same organism were available at the time of experimentation. Even though different species (rat and human) were used, careful analysis of the data in relation to the sequence differences of the isoforms used, still yields valuable insights in to the molecular basis of peptide:channel interaction.
NMR data acquisition and structural analysis. 13 C/ 15 N-labelled peptide in 20 mM potassium phosphate buffer, pH 5 containing 5% D 2 O was filtered using a low-protein-binding Ultrafree-MC centrifugal filter (0.22 µm pore size; Millipore, MA, USA), then 300 μL of ~300 μM was added to a susceptibility-matched 5 mm outer-diameter microtube (Shigemi Inc.). NMR spectra were acquired at 298 K on a 900 MHz Bruker AVANCE II+ spectrometer (Bruker BioSpin) equipped with a cryogenically cooled probe. Data used for resonance assignment were acquired using non-uniform sampling (NUS); sampling schedules that approximated the rate of signal decay along the various indirect dimensions were generated using sched3D 59 . The decay rates used were 1 Hz for all constant-time 15 NUS data were processed using the Rowland NMR toolkit (www.rowland.org/rnmrtk/toolkit.html); maximum entropy parameters were selected automatically as described 60 . NMR spectra were analysed and assigned using the program XEASY 61 or SPARKY 62 . 1 H N , 15 N, 13 C α , 13 C β , and 13 C′ resonance assignments were obtained from analysis of amide-proton strips in 3D HNCACB, CBCA(CO)NH, and HNCO spectra. Side-chain 1 H and 13 C chemical shifts were obtained primarily from 3D H(CC) (CO)NH-TOCSY and (H)CC(CO)NH-TOCSY spectra, respectively. The remaining side-chain assignments were derived from 3D 15 N-and 13 C-edited NOESY-HSQC spectra. The program TALOS+ 31 was used to predict the secondary structure of the peptide. Disulfide connectives were determined from NOESY patterns 59 . During the automated NOESY assignment/structure calculation process, CYANA assigned 90.1% of all NOESY cross-peaks (829 of 920).
Automated patch clamp analyses on Na V channel-expressing mammalian cells. For patch clamp
analysis, HEK293 cells stably co-expressing the hNa V 1.1, hNa V 1.6, or hNa V 1.7 α-subunit with the Na V β 1 -subunit (SB Drug Discovery) were cultured following manufacturer guidelines. Cells were removed from culture at 70% confluency using Detachin (Genlantis) and resuspended to 5 × 10 6 cells/mL in Ex-Cell ACF CHO Medium (Life Technologies) supplemented with 25 mM HEPES (Sigma-Aldrich) and 1 × Glutamax (Life Technologies) before being transferred to the Q-Patch Q-Stirrer and allowed to recover for 30 min before assay.
The external solution contained (in mM): 140 NaCl, 4 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, 20 TEA-Cl, 10 glucose, pH 7.4 (with NaOH) and adjusted to 315 mOsm 0.05% BSA was added to prevent adsorptive loss of peptide. The intracellular solution contained (in mM): 140 CsF, 1/5 EGTA/CsOH, 10 HEPES and 10 NaCl, pH 7.4 (with CsOH) and adjusted to 320 mOsm. Whole-cell patch-clamp experiments were performed at room temperature on a QPatch-16 automated electrophysiology platform (Biolin Scientific) using 16-channel planar patch chip plates (Q-Plates) with a patch hole diameter of 1 µm and resistance of 2 ± 0.1 MΩ. Cell positioning and sealing parameters were set as follows: positioning pressure −60 mbar, minimum seal resistance 0.1 GΩ, holding potential −90 mV and holding pressure −20 mbar. Whole-cell currents were filtered at 5 kHz (8-pole Bessel) and digitised at 25 kHz. A P/6 online leak-subtraction protocol was used with non-leak-subtracted currents acquired in parallel. Cells were maintained with holding potentials of −80 (hNa V 1.1) or −100 mV (hNa V 1.6 and hNa V 1.7) between protocols, respectively and depolarised to −10 mV with a sweep interval of 20 s to allow complete recovery from inactivation between sweeps. Pre1a concentrations were incubated for a fixed time of 5-10 min to allow steady-state activity, monitored by the I-T plot.
Patch clamp analyses of SH-SY5Y cells and rat DRG neurons. Whole-cell patch clamp electrophys-
iology was carried out on SH-SY5Y cells as described previously 42 or from small (<25 μm diameter) acutely isolated adult male rat DRG neurons as described previously 63 . DRG neurons were taken from rats that had undergone either partial ligation of the left sciatic nerve (PNL) to induce a state of neuropathic pain (defined as development of significant mechanical allodynia seven days after surgery) or sham operated rats 64 . SH-SY5Y cells were used within 24-72 h, and DRG neurons were used within 6 hours of plating. Only cells with minimal or no processes were used. Whole-cell patch-clamp recordings were performed at room temperature with fire-polished patch electrodes prepared from borosilicate glass (SDR Clinical Technology). Electrode resistance was 3.5-5 MΩ when filled with an internal solution containing (composition in mM): 120 CsCl, 5 MgATP, 5 NaCl, 2 CaCl 2 , 20 HEPES, 10 EGTA, pH 7.3 and adjusted to 283-286 mOsm. Cells were continuously bathed in a HEPES-buffered physiological saline (HBS; composition in mM): 155 NaCl, 2.5 KCl, 1.8 CaCl 2 , 1.2 MgCl 2 , 10 HEPES, 10 glucose, pH 7.4 (adjusted with NaOH) and adjusted to 328-331 mOsm. Currents were recorded using a HEKA EPC-9 amplifier and PULSE software (v8.8, HEKA Elektronik, Lambrecht/Pfalz, Germany). Data was filtered at 4 kHz and sampled at 20 kHz. Series resistance was compensated by 80%. Capacitance transients were compensated and leak subtraction was performed with a P/8 online protocol. Drugs were applied to cells using a gravity-fed superfusion system (250 μm diameter) positioned directly above the cell resulting in rapid solution exchange (<500 ms).
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